Hims & Hers Looks to Expand Globally With Buy of Australian Telehealth Provider - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion DealBy [Mackenzie Tatananni]ShareR ...

Core Insights - Hims & Hers Health, Inc. (HIMS) has experienced a significant decline of approximately 50% year-to-date, marking a continuous downward trend since the initial coverage began [1] Company Performance - The stock has dropped 50% since the first coverage, indicating a persistent negative momentum in its market performance [1] Analyst Background - The analysis is provided by a retired Wall Street portfolio manager with over two decades of experience in the technology, media, and telecommunications (TMT) sectors, emphasizing a focus on risk mitigation and momentum strategies [1]

The positive movement follows the announcement of a definitive agreement to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers’ international presence.Hims & Hers agreed to acquire Eucalyptus, which operates in multiple countries, including Australia, the U.K., and Germany.The deal is structured to maintain financial flexibility, with the company planning to finance most of the transaction using existing cash and future operating cash flows.Deal ConsiderationThe transactio ...

Core Viewpoint - Hims & Hers Health shares experienced a rally following the announcement of a deal to acquire an Australia-based telehealth provider [1] Company Summary - Hims & Hers Health is expanding its services through the acquisition of a telehealth provider based in Australia [1] Industry Summary - The health-and-wellness sector is seeing increased consolidation as companies seek to enhance their telehealth offerings [1]

根据交易条款，交易完成后Hims需支付近2.4亿美元现金。Eucalyptus还可在未来18个月内获得递延业绩 对价，并有望在2029年初前根据财务目标完成情况收取额外款项。 Hims可选择以现金或股票形式支付大部分递延及业绩对价。 智通财经APP获悉，Hims & Hers Health(HIMS.US)宣布将以现金加股票的方式收购澳大利亚数字健康服 务商Eucalyptus，交易价值最高可达11.5亿美元。受此消息提振，该公司股价周四美股盘前上涨约7%。 总部位于悉尼的Eucalyptus年营收规模超4.5亿美元，是澳大利亚规模最大的数字健康服务商。Hims预 计，此次收购将助力其拓展澳大利亚与日本市场，并进一步扩大在英国、德国和加拿大的业务布局。 据了解，总部位于美国加州旧金山的Hims主营减重药物复方制剂销售，预计本次交易资金主要来自公 司现有现金及美国业务的运营现金流。该交易预计于2026年年中完成。 ...

Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth ProviderBy [Mackenzie Tat ...

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach. ...

Core Viewpoint - Hims & Hers Health is acquiring Australian digital health company Eucalyptus for a deal valued at up to $1.15 billion, aiming to expand its personalized telehealth services [1] Group 1: Acquisition Details - The acquisition is valued at up to $1.15 billion, indicating a significant investment in expanding digital health capabilities [1] - Eucalyptus is recognized for its innovative approach in the digital health sector, which aligns with Hims & Hers Health's strategy to enhance its service offerings [1] Group 2: Strategic Intent - The acquisition reflects Hims & Hers Health's commitment to broadening its telehealth platform and enhancing personalized healthcare solutions [1] - This move is part of a larger trend in the healthcare industry where companies are increasingly focusing on digital health solutions to meet consumer demands [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Insights - Carillon Tower Advisers reported that small-cap stocks had marginal gains in Q4 2025, with the Russell 2000 Growth Index returning 13.01% and the Russell 2000 Value Index gaining 12.58% [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in sectors such as Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending as they head into 2026 [1] Company Analysis: Hims & Hers Health, Inc. (NYSE:HIMS) - Hims & Hers Health, Inc. is a leading telehealth platform offering a variety of health and wellness products and services, with a market capitalization of $3.704 billion [2] - The stock closed at $16.27 per share on February 17, 2026, with a one-month return of -43.68% and a 12-month decline of 76.33% [2] - The company has faced challenges due to regulatory changes and competition from major pharmaceutical companies, despite initial growth from its injectable GLP-1 weight loss drugs launched in May 2024 [3] - Hims & Hers is diversifying its offerings to include hormone replacement therapy and peptides for health and aging, positioning itself for long-term growth despite cautious near-term investor sentiment [3] Hedge Fund Interest - Hims & Hers Health, Inc. was held by 35 hedge fund portfolios at the end of Q3 2025, an increase from 34 in the previous quarter [4] - While the company shows potential as an investment, certain AI stocks are considered to offer greater upside potential with less downside risk [4]